Arcellx, Inc.
ACLX
Rank in Stocks
#2779
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Share Price
$115.07
Last synced: 2026-05-15
Market Cap
$6.73B
Change (1 day)
0.00%
Change (1 year)
32.28%
Country
US
Trade Arcellx, Inc. (ACLX)
Category
Healthcare
Earnings for Arcellx, Inc. (ACLX)
Earnings in Dec 2025 TTM: $-228.87M
According to Arcellx, Inc. latest financial reports the company's current earnings are $-228.87M. In 2023 the company made an earning of $-70.03M, an increase over its 2022 earnings that were of $-188.68M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Arcellx, Inc. from 2018 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-228.87M | 117.39% |
| 2024 | $-105.28M | 50.34% |
| 2023 | $-70.03M | -62.89% |
| 2022 | $-188.68M | 190.41% |
| 2021 | $-64.97M | 102.43% |
| 2020 | $-32.10M | 78.58% |
| 2019 | $-17.97M | 116.32% |
| 2018 | $-8.31M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | -2,404.81% |
US
|
|
| $-3.09B | 1,248.83% |
US
|
|
| $-4.02B | 1,654.83% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -952.31% |
NL
|
